información sobre la mifepristona, el metotrexate y el misoprostol

inicio preguntas

antecedentes legales



You can read this page in English; Vous pouvez aussi lire cette page en français;  
You can read this page in Arabic
You can read this website in Persian

  • ACOG Practice Bulletin. 2001; no. 26.
  • merican Psychological Association, Task Force on Mental Health and Abortion. Report of the Task Force on Mental Health and Abortion. Washington, DC: Author, 2008.
  • Baird D. Mode of action of medical methods of abortion. JAMWA. 2000; 35(3): S121-126.
  • Barbosa R, Arilha M. The Brazilian experience with Cytotec. Studies in Family Planning. 1993; 24(4): 236-240.
  • Bebbington M, Kent N, Lim K, Gagnon A, Delisle M, Tessier F, Wilson R. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet. Gynecol. 2002; 187(4): 853-857.
  • Benson J, Clark K, Gerhardt A, Randall L, Dudley S. Early abortion services in the United States: Ensuring service availability, remaining on the cutting edge of technology, and responding to client demand. Chapel Hill, NC: IPAS, 2001.
  • Beral V, Bull D, Doll R, et al. Breast cancer and abortion: Collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet. 2004;363(9414):1007-16.
  • Blanchard K, Winikoff B, Ellertson C. Misoprostol used alone for the termination of early pregnancy: A review of the evidence. Contraception 1999; 59: 209-217.
  • Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: A review. Am J Obstet Gynecol. 2002; 99(2): 316-332.
  • Boonstra H. Mifepristone in the United States: Status and future. The Guttmacher Report on Public Policy. 2002: 4-7.
  • Bugalho A, Mocumbi S, Faúndes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 µg of vaginal misoprostol. Contraception. 2000; 61: 47-50.
  • Bygdeman M, Gemzell K, Marions L. Medical termination of early pregnancy: The Swedish experience. JAMWA. 2000; 35(3): S195-196.
  • Carbonell J, Rodrigues J, Aragón S, Velazco A, Tanda R, Sánchez C, Barambio S, Chami S, Valero F. Vaginal misoprostol 1000 µg for early abortion. Contraception 2001; 63: 131-136.
  • Carbonell Esteve J, Varela L, Velazco L, Cabezas A, Tanda R, Sánchez C. Vaginal misoprostol for late first trimester abortion. Contraception. 1998; 57: 329-333.
  • Carbonell Esteve J, Varela L, Velazco A., Tanda R, Cabezas E, Sánchez C. Early abortion with 800 µg of misoprostol by the vaginal route. Contraception. 1999; 59; 219-225.
  • Charles V, Polis C, Sridhara S, Blum R. Abortion and long-term mental health outcomes: a systematic review of the evidence. Contraception 2008;78:436-50.
  • Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: The impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. JAMWA. 2000; 35(3): S177-182.
  • Cheng L, Gülmezoglu A, Piaggio G, Ezcurra E, Van Look P. Interventions for emergency contraception. Cochrane Database Syst Rev. 2008, Issue 2.
  • Costa S, Vessey M. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993; 341: 1258-1261.
  • Coyaji K. Early medical abortion in India: Three studies and their implications for abortion services. JAMWA. 2000; 35(3): S191-194.
  • Creinin M, Schwartz J, Guido R, Pymar H. Early pregnancy failure-Current management concepts. Obstetrical and Gynecological Survey. 2001; 56(2): 105-113.
  • Creinin M. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol. 2000; 183: S3-S9.
  • Creinin M, Pymar H. Medical abortion alternatives to mifepristone. JAMWA. 2000; 35(3): S127-132.
  • Creinin M, Carbonell J, Schwartz J, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999; 59(1): 217-221.
  • Ellertson C, Elul B, Winikoff B. Can women use medical abortion without medical supervision? Reproductive Health Matters. 1997; 9: 149-161.
  • Ellertson C, Waldman S. The mifepristone-misoprostol regimen for early medical abortion. Current Women's Health Reports 2001; 1: 184-190.
  • Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: Thoughts on the method and home administration of misoprostol. JAMWA. 2000; 35(3): S169-172.
  • Ewart W, Winikoff B. Toward safe and effective medical abortion. Science. 1998; 281: 520-521.
  • Finer L, Henshaw S. Abortion incidence and services in the United States in 2000. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 6-15.
  • Glick E. Surgical Abortion. Reno, NV: West End Women's Medical Group, 1998.
  • Hamoda H, Ashok P, Stalder C, Flett G, Kennedy E, Templeton A. A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstet Gynecol. 2004;104:1307-13.
  • Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? Contraception 2002; 65(2): 133-142.
  • Harvey S, Sherman C, Bird S, Warren J. Understanding medical abortion: Policy, politics, and women's health. Eugene, OR: Center for the Study of Women in Society, 2002.
  • Henshaw S, Finer L. The accessibility of abortion services in the United States, 2001. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 16-24.
  • Jain J, Dutton C, Harwood B, Meckstroth K, Mishell D. A prospective randomize, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reproduction 2002; 17(6): 1477-1482.
  • Jain J, Kuo J, Mishell D. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Am J Obstet. Gynecol. 1999; 93(4): 571-575.
  • Jones R, Darroch J, Henshaw S. Patterns in the socioeconomic characteristics of women obtaining abortion in 2000-2001. Perspectives on Sexual and Reproductive Health. 2002; 34(5): 226-235.
  • Jones R, Henshaw S. Mifepristone for early medical abortion: Experiences in France, Great
  • Britain and Sweden. Perspectives on Sexual and Reproductive Health. 2002; 34(3): 154-161.
  • Kahn J, Becker B, MacIsaac L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000; 61:29-40.
  • Kruse B. Advanced practice clinicians and medical abortion: Increasing access to care. JAMWA. 2000; 35(3): S167-168.
  • Melbye M, Wohlfahrt J, Olsen J, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997; 336(2): 81-85.
  • National Abortion Federation. Early medical abortion with mifepristone and other agents: Overview and protocol recommendations. Washington, DC: NAF, 2002.
  • Newhall E, Winikoff B. Abortion with mifepristone and misoprostol: Regimens, efficacy, acceptability and future directions. Am J Obstet Gyncol. 2000; 183(2): S44-53.
  • Ngai S, Tang O, Chan Y, Ho P. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: Efficacy and acceptability. Human Reproduction. 2000; 15(5): 1159-1162.
  • Philip N, Shannon C, and Winikoff B. Misoprostol and teratogenicity: Reviewing the evidence–Report of a meeting. Robert H. Ebert Program on Critical Issues in Reproductive Health Publication Series. New York: Population Council, 2003.
  • Pymar H, Creinin M. Alternatives to mifepristone regimens for medical abortion. Am J Obstet Gyncol. 2000; 183(2). S54-64.
  • Rodger M, Baird D. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analog (gemeprost). Contraception. 1997; 56(3): 165-168.
  • Rosing M, Archbald C. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. JAMWA. 2000; 35(3): S183-185.
  • Schaff E, Fielding S. A comparison of the abortion rights mobilization and Population Council trials. JAMWA. 2000; 35(3): S137-140.
  • Schaff E, Fielding S, Westhoff C, Ellertson C, Eisinger Stadalius L, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMWA. 2000; 284(15): 1948-1953
  • Shangchun, W. Medical abortion in China. JAMWA. 2000; 35(3): S197-199.
  • Spitz I, Bardin C, Benton L, and Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Eng J Med. 1998; 338: 1241-1247.
  • Stewart F, Wells E, Flinn S, Weitz T. Early medical abortion: Issues for practice. San Francisco, CA: UCSF, Center for Reproductive Health Research and Policy, 2000.
  • Steinberg J, Russo N. Abortion and anxiety: what's the relationship? Soc Sci Med 2008;67:238–52.
  • Tang O, Miao B, Lee S, Ho P. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: Efficacy and acceptability.Human Reproduction 2002; 17(3): 654-658.
  • Tang O, Ho P. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception 2001; 64: 315-317.
  • Ulmann A. The development of mifepristone: A pharmaceutical drama in three acts. JAMWA. 2000; 35(3): S117-120.
  • von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S, Cheng W, Lüdicke F, Pretnar-Darovec A, Kirkman R, Mittal S, Khomassuridze A, Apter D, Peregoudov A. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803-10.
  • von Hertzen H. Research on regimens for early medical abortion. JAMWA. 2000; 35(3): S133-136.
  • Weitz T, Foster A, Ellertson C, Grossman D, Stewart F. “Medical” and “surgical” abortion: Rethinking the modifiers. Contraception 2004:69;77-78.
  • World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ. 1993; 307 (6903): 532-537.


Your access and use of this website is subject to certain terms of use. By viewing web pages in this site, you accept, without limitation or qualification, these terms. Read our privacy statement. Last updated: September 2014.